Centrus Energy (LEU) has completed a $500 million capital raise with a structure that could significantly expand its shareholder base. The package, priced late Wednesday, includes common stock, pre-funded warrants, and four series of common warrants that collectively could add nearly 48% to the company's outstanding shares. Investors are closely watching the potential dilution, which could reshape the ownership landscape for the nuclear fuel supplier.
The offering consists of 500,000 Class A shares and pre-funded warrants covering 2,005,513 shares. Buyers also receive four series of common warrants exercisable for up to 6,992,382 additional shares. If all instruments are converted, the total new shares would reach 9,497,895, representing 47.6% of the 19.95 million Class A and Class B shares reported as of June 30. This substantial potential dilution is a key factor for existing shareholders to consider.
LEU shares closed Wednesday at $181.49, but in after-hours trading they fell to $174.00, down 4.1%, according to Yahoo Finance. The offering is expected to close on September 11, subject to customary conditions. The market's reaction suggests investors are weighing the potential dilution against the capital infusion.
Understanding the Pricing Structure
The headline offer price of $199.64 per share and accompanying warrants appears generous, representing a 10% premium over Wednesday's close. Pre-funded warrant packages were priced at $199.54, reflecting their $0.10 exercise price. However, this apparent premium is misleading because investors are not just buying common stock—they also receive proportional interests in four warrant series. The true economic comparison must account for the option value of these warrants, which explains why the after-hours share price moved downward despite the apparent premium.
Immediate Dilution
The first layer of dilution is relatively straightforward. Treating pre-funded warrants as shares, Centrus would add 2.51 million shares immediately, a 12.6% increase over the June 30 count. This would reduce existing shareholders' ownership by about 11.2%, before any common warrants are exercised. This immediate dilution is already reflected in the after-hours trading activity.
Conditional Dilution from Warrants
The second layer is larger but conditional. The common warrants have exercise prices of $226.8625, $272.2350, $317.6075, and $362.9800, which are 25%, 50%, 75%, and 100% above Wednesday's closing price, respectively. The warrants expire in two tranches, with the second tranche lasting nine weeks longer. According to Centrus, full exercise of each warrant series would generate approximately $500 million, potentially bringing in an additional $2 billion if all are exercised. This would result in a 47.6% increase in shares, and existing shareholders would see their ownership diluted by 32.3%, retaining about 67.7% of the pro forma total.
Use of Proceeds and Financial Position
Centrus is not in a distressed financial situation. The company reported $1.87 billion in cash and cash equivalents and $1.18 billion in long-term debt as of June 30. Its backlog stood at $4.5 billion, though $3.0 billion of that was contingent on LEU and HALEU sales contracts. Capital expenditures in the first half totaled $94.8 million, up from $5.7 million a year earlier. The company has broad discretion over the proceeds, including working capital, technology development, debt repayment, capital spending, and possible acquisitions. This flexibility is useful for scaling U.S. enrichment capacity but leaves investors without a specific project to evaluate.
At Wednesday's close, the equity value based on June's share count was approximately $3.62 billion. The initial raise equals about 14% of that value, while all potential cash from the offering and warrant exercises could approach $2.5 billion, or 69%. This financing significantly increases Centrus's resources, but management must deploy the capital at returns high enough to offset the larger claim on future profits.
Market Implications and Investor Outlook
The near-term debate is not about whether all 6.99 million common warrants will be exercised immediately—they will not—but about the overhang they create. If the stock climbs through the escalating strike prices, Centrus gains more capital while shareholders absorb more dilution. If the stock stays below them, the warrants expire worthless, and the company does not receive the additional cash. The bullish case is that a well-funded domestic enrichment platform can capitalize on scarce U.S. capability, policy support, and long-term demand. The bearish case is that part of the backlog is contingent, deployment is capital-intensive, and this financing transfers significant upside to new warrant holders.
Investors should focus on specific capital allocation decisions: firm contracts, capacity milestones, committed budgets, and how management uses the initial $500 million. The $199.64 offer price is not the right benchmark. Instead, the framework is a $500 million cash infusion now, potentially $2 billion later, and a share count that could rise 47.6%. The next decision-useful evidence will be whether Centrus can generate returns that exceed the dilution cost.
